Renaissance Technologies’s Tourmaline Bio TRML Stock Holding History

Renaissance Technologies’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-91,850	Closed	-$4.39M	–	3767
2025 Q3	$4.39M	Buy	+91,850	New	+$2.55M	0.01%	1578
2024 Q3	–	Sell	-100,076	Closed	-$1.29M	–	3894
2024 Q2	$1.29M	Buy	100,076 +64,950	+185%	+$1.05M	﹤0.01%	2175
2024 Q1	$804K	Buy	35,126 +1,150	+3%	+$40.6K	﹤0.01%	2623
2023 Q4	$889K	Buy	33,976 +14,329	+73%	+$287K	﹤0.01%	2485
2023 Q3	$552K	Sell	19,647 -24,433	-55%	-$715K	﹤0.01%	2665
2023 Q2	$1.34M	Buy	44,080 +38,540	+696%	+$984K	﹤0.01%	2271
2023 Q1	$104K	Buy	5,540 +3,460	+166%	+$57.1K	﹤0.01%	3484
2022 Q4	$21K	Buy	+2,080	New	+$33.4K	﹤0.01%	3953

Renaissance Technologies's TRML Position: Q4 2025 in Review

Renaissance Technologies sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 91,850 shares — an estimated $4.39M sold.

Renaissance Technologies first reported a position in TRML in Q4 2022 and held it in 8 quarters. The position peaked at $4.39M in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

Renaissance Technologies reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
Renaissance Technologies sold 91,850 Tourmaline Bio shares in Q4 2025, an estimated $4.39M.
Renaissance Technologies first reported a position in Tourmaline Bio in Q4 2022 and held it in 8 quarters.
Renaissance Technologies's Tourmaline Bio position peaked at $4.39M in Q3 2025.
0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on Renaissance Technologies's 13F filing for Q4 2025, filed 12 Feb 2026.